The goal of this clinical trial is to test alpha lipoic acid in children undergoing hemodialysis. The main questions it aims to answer are:
* Will the use of alpha lipoic acid lower cardiovascular events in that population?
* Is the incidence of those cardiovascular events linked to the oxidative stress and endothelial dysfunction in that population?
* Will the drug cause side effects?
Participants will:
* take either one dose daily of 600mg tablet Alpha lipoic acid orally or a look-alike tablet containing no drug.
* be monitored for the occurrence of cardiovascular events (stroke, angina, etc.)
* be monitored for the occurrence of side effects
* give blood samples for testing serum levels of E-selectin biomarker and superoxide dismutase enzyme
* undergo clinical examinations (Echocardiogram, Duplex ultrasonography, Intima-Media-Thickness) Researchers will compare between the group taking alpha lipoic acid and the group taking the look-alike tablet.

Start Date01 Jan 2025

Sponsor / Collaborator

Ain Shams University

[+1]

NCT05713799 / Not yet recruitingPhase 2IIT

Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity

Background:
Obesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist for obesity that are safe and widely available. A study drug (mirabegron [MG]) combined with a supplement (alpha-lipoic acid [ALA]) may help.
Objective:
To learn how MG and ALA can help the body process food.
Eligibility:
People aged 18 to 65 years with a body mass index between 30 and 40 kg/m2.
Design:
Participants will be screened. They will have a physical exam. They will have blood and urine tests and a test of their heart function. They will speak with a dietician.
The study has two phases. Each phase begins with a 2-day stay in the clinic; then the participant will take the study drugs at home for about 4 weeks, followed by another 2-day stay in the clinic. They will also have outpatient visits about 2 weeks after each clinic stay.
During the clinic stays, participants will undergo many tests:
They will have a plastic tube (catheter) inserted into a vein in each arm. These will be used to draw blood and to infuse glucose (sugar) and insulin.
They will have imaging scans.
They will have a clear hard plastic shield placed over their head to measure oxygen and carbon dioxide as they breathe.
Participants will take the study drugs at home. Both MG and ALA are taken by mouth with water. During one phase, participants will take MG plus a placebo. A placebo looks like the study drug but doesn t contain medicine.
They will log their diet, exercise, and sleep....

Start Date25 Dec 2024

Sponsor / Collaborator

National Institute of Diabetes & Digestive & Kidney Diseases

NCT05083546 / Not yet recruitingPhase 1/2IIT

Testing the Impact of a Combination of Dietary Supplements With Multimodal Effects on Longevity Mechanisms on Reducing Body Weight and Delaying Aging

Mechanisms that drive addiction to sugar rich foods are a major driving factor in the pathogenesis of obesity, which has become one of the most significant health care burdens. The molecular underpinnings of these hedonic mechanisms that drive addiction to sugar are poorly understood. The investigators demonstrated that methylglyoxal (MGO) derived Advanced Glycation Endproducts (AGEs) enhance food intake especially under a high sugar diet. The investigators identified a methylglyoxal (MGO) lowering cocktail, Gly-low, a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine that demonstrates a multimodal effect influencing many pathways related to aging including calorie restriction. Glycation lowering (Gly-low) treatment significantly reduces food intake and weight gain in the db/db mice that lack the leptin receptor. The investigators also extended the lifespan of C57BL/6 mice fed with these compounds starting when they were 24 months old. Based on these results, the investigators hypothesized that methylglyoxal (MGO) lowering cocktail of compounds can be given to adults with obesity, specified as body mass index (BMI) >27, to lower serum and urinary markers of insulin resistance, lower boy mass index (BMI), and lower food intake.

Start Date01 Dec 2024

Sponsor / Collaborator

The University of California, San Francisco

100 Clinical Results associated with Lipoic acid

100 Translational Medicine associated with Lipoic acid

100 Patents (Medical) associated with Lipoic acid

6,973

Literatures (Medical) associated with Lipoic acid

01 Dec 2025·Current Urology Reports

Management Strategies for Patients with Non-Infectious Cystitis: A Review of the Literature

Review

Author: Sawyer, Kathryn ; Zheng, Yu ; Gupta, Priyanka ; Aqeel, Jawad

PURPOSE OF REVIEW:

The management of noninfectious cystitis continues to evolve as new treatments continue to be developed and investigated. This review aims to synthesize the most recent data regarding management strategies for noninfectious cystitis focused on non-ulcerative, ulcerative, eosinophilic, and ketamine-induced cystitis.

RECENT FINDINGS:

Several novel treatments have shown promise as management options including combination antihistamine therapy, phosphodiesterase 5 inhibitors, alpha lipoic acid supplements, and onabotulinumtoxin A. Recent studies have also found pentosan polysulfate sodium to have adverse ophthalmologic effects. For patients with ulcerative cystitis, recent research has shown that fulguration with or without triamcinolone injections should not be delayed. The treatment of noninfectious cystitis should be patient specific based on factors including etiology and symptom profile. Multimodal regimens are often the most effective. Treatment should be started with conservative options and escalated as necessary to oral treatments, intravesical options, or procedural management.

01 Feb 2025·NEUROCHEMICAL RESEARCH

Ferroptosis in the Substantia Nigra Pars Compacta of Mice: Triggering Role of Ultrafine Diesel Exhaust Particles and Mitigation by α-Lipoic Acid

Article

Author: Kim, Ji Young ; Seo, Je Hoon ; Kim, Yong-Dae ; Shin, Dong-Ick ; Kim, Aryun ; Gil, Young-Chun ; Kim, Jin-Hee

Recent epidemiological and experimental studies have increasingly highlighted the association between environmental pollution, especially ultrafine particulate matter (PM), and the risk of neurodegenerative diseases, such as Parkinson's disease (PD). These previous studies suggest a potential mechanism by which ultrafine PM contributes to neuronal damage through processes, such as iron accumulation and oxidative stress. In this study, we aimed to elucidate the effects of ultrafine PM on ferroptosis, an iron-dependent form of cell death, in the mouse substantia nigra pars compacta (SNc) and to evaluate the protective role of α-lipoic acid (ALA). Mice were exposed to ultrafine diesel exhaust particles (ufDEP), a type of ultrafine PM, intranasally and injected ALA intraperitoneally for seven consecutive days. Iron accumulation and lipid peroxidation were significantly increased, and antioxidant capacity was significantly decreased in the SNc after ufDEP exposure, highlighting the deleterious effects of ufDEP on tyrosine hydroxylase (TH)-positive neurons. In contrast, ALA treatment effectively mitigated these effects by reducing iron accumulation, decreasing lipid peroxidation, and restoring antioxidant levels, resulting in the protection of TH-positive neurons from ferroptotic damage. Our results provide evidence that ufDEP can induce ferroptosis in dopaminergic neurons in the SNc, potentially contributing to PD pathogenesis. Furthermore, ALA showed protective effects against ufDEP-induced ferroptotic damage, suggesting its potential as a therapeutic intervention for PD.

01 Feb 2025·FISH & SHELLFISH IMMUNOLOGY

Effects of α-lipoic acid (LA) supplementation in high-fat diet on the growth, glycolipid metabolism and liver health of largemouth bass (Micropterus salmoides)

Review

Author: Chi, Shuyan ; Chen, Jiandong ; Tan, Beiping ; Cheng, Tao

An 8-week feeding trial was conducted to investigate the effects of LA supplementation in a high-fat diet on the growth performance, hepatic antioxidant capacity, and glycogen metabolism of largemouth bass (Micropterus salmoides). Five diets were formulated including control diet (11.55 % crude fat, CF), a high-fat diet (17.80 % crude fat, HF) and three HF diets supplemented with 0.15 %, 0.20 % and 0.25 % LA (HL0.15, HL0.20 and HL0.25, respectively). In this experiments, HL0.15 and HL0.20 could improve the uniform for the growth of the largemouth bass, while adding 0.25 % did not significantly improve growth. The highest viscerosomatic index (VSI) and hepatosomatic index (HSI) were measured in fish fed the HF diet. Compared to the fish fed HF diet, fish fed HL diets showed lower serum total triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), hepatic malondialdehyde (MDA) and glycogen levels, and higher hepatic catalase (CAT) and glutathione peroxidase (GSH-PX) activities. In addition, the mRNA expression for lipolysis genes in fish liver were increased and for gluconeogenesis and fatty acid synthesis were reduced. The transcript levels of apoptosis-related genes were significantly down-regulated in the liver of largemouth bass in HL0.15 and HL0.20 groups compared to the HF group. Moreover, compared with the HF group, the mRNA expression of pro-inflammatory factors was significantly reduced in HL groups, and the histomorphology of the liver were significantly improved. These results suggested that LA supplementation in high-fat diets could improve lipid utilization, glycogen accumulation, antioxidant capacity of fish liver, thus reduce the adverse effects of high fat diets on fish, and then improve the growth performance of largemouth bass.

News (Medical) associated with Lipoic acid

01 Aug 2024

·www.prnewswire.com

Livity Wellness Introduces New IV Therapy Offerings in South Florida

MIAMI, Aug. 1, 2024 /PRNewswire/ -- Livity Wellness, a pioneer in holistic health and wellness, is thrilled to announce the addition of PlaqueX and Alpha Lipoic Acid IV Therapy to its suite of services in South Florida. As one of the select providers in the region offering these treatments, Livity Wellness continues to expand its innovative intravenous therapy options, which are dedicated to promoting overall wellness and vitality. Advanced IV Therapy Solutions Continue Reading Alpha Lipoic Acid Livity Wellness is enhancing the wellness landscape with its new PlaqueX and Alpha Lipoic Acid IV Therapy. This treatment combines phosphatidylcholine (PlaqueX) and alpha lipoic acid (ALA) to offer unique health benefits that are currently under scientific investigation. Phosphatidylcholine (PlaqueX) Phosphatidylcholine is a vital component of cell membranes and is essential for cellular function. Preliminary studies suggest that PlaqueX may play a role in maintaining cardiovascular health by potentially breaking down arterial plaque, which could reduce the risk of heart disease and stroke. Additionally, it is being studied for its potential to support liver function and enhance the body's natural detoxification processes. However, it is important to note that these claims have not been evaluated or approved by the FDA, and ongoing research aims to further understand its benefits and efficacy. Alpha Lipoic Acid (ALA) Alpha Lipoic Acid is a potent antioxidant that combats oxidative stress and inflammation. Current research indicates that ALA may regenerate other critical antioxidants, such as vitamins C and E. It is also being studied for its potential to support healthy blood sugar levels and improve insulin sensitivity, which may be beneficial for individuals managing diabetes or metabolic syndrome. Like PlaqueX, the specific health claims related to ALA have not been approved by the FDA, and further studies are needed to validate its therapeutic potential. Enhanced Antioxidant Support: Adding Glutathione Livity Wellness takes IV therapy a step further by incorporating glutathione, another powerful antioxidant, into their treatments. Glutathione is known for its role in detoxifying the body, reducing oxidative stress, and supporting the immune system. The combination of glutathione with PlaqueX and ALA is intended to enhance the overall antioxidant capacity, creating a synergistic effect that may maximize cellular protection and repair. These health claims are based on preliminary research and have not been approved by the FDA, emphasizing the need for ongoing scientific exploration. Commitment to Wellness and Innovation Livity Wellness is committed to offering innovative and evidence-based treatments to its clients. By introducing PlaqueX and Alpha Lipoic Acid IV Therapy, the clinic aims to provide advanced options for those seeking to enhance their wellness journey. While the potential benefits of these therapies are promising, Livity Wellness encourages clients to stay informed about the latest research findings and to consult with healthcare professionals before starting any new treatment regimen. For more information about Livity Wellness and its IV therapy offerings, please visit our website or contact us directly. References For further reading on the research related to these therapies, please see the following sources: What Sets Livity Wellness Apart? Superior Absorption and Efficacy IV therapy at Livity Wellness delivers nutrients directly into the bloodstream, bypassing the digestive system for 100% absorption and immediate benefits. This direct infusion ensures higher concentrations and more rapid absorption than oral supplements, providing unmatched bioavailability and potency. Customized Wellness Plans Every client's journey to optimal health is unique. Livity Wellness's skilled practitioners craft personalized IV therapy plans tailored to each individual's specific needs and objectives, whether enhancing cardiovascular health, supporting liver function, or improving overall well-being. Professional Care and Safety At Livity Wellness, client safety, and comfort are paramount. Their highly trained professionals meticulously monitor the infusion process, ensuring a seamless and relaxing experience. Treatment durations and frequencies are customized to meet each client's unique health requirements. Real Stories, Real Transformations Carlos R. from Miami Beach, FL: "Livity Wellness's IV therapy has transformed my life. The personalized blends boosted my energy and improved my health. The convenience of having therapy at home is unbeatable. I highly recommend them!" Maria L. from Coral Gables, FL: "After years of chronic fatigue, Livity Wellness's IV therapy has been a revelation. I feel more energized and healthier. The team is professional and ensures a comfortable experience every time." About Livity Wellness Livity Wellness is South Florida's premier destination for holistic health and wellness optimization. Offering on-demand wellness services, including personalized IV therapy, weight loss management, and acute care treatments, Livity Wellness delivers top-tier health solutions directly to clients' doorsteps. By seamlessly blending advanced science with personalized care, Livity Wellness helps clients achieve their ultimate health and wellness goals. Contact Information: Livity Wellness Website: Phone: 786-936-3190 Email: [email protected] Address: 6303 Waterford District Dr., Miami, FL 33126 Media Contact: OmniFunnel Marketing Public Relations Manager - Livity Wellness Email: [email protected] Website: Phone: 1-866-673-9306 SOURCE Livity Wellness

23 Oct 2023

·www.prnewswire.com

REVIVELE LAUNCHES COMPREHENSIVE WOMEN'S SUPPLEMENT SYSTEM

Essentials by Revivele Takes the Guesswork out of Women's Supplementation with a System Designed to Support Cognitive Function, Balance Hormones, and Help Prevent Disease MIAMI, Oct. 23, 2023 /PRNewswire/ -- Revivele, the pharmacist-founded healthcare company empowering women to take control of their own health, has launched Essentials by Revivele, a comprehensive, easy-to-use supplement system tailored specifically to help improve and support women's overall health and longevity, especially as they enter their perimenopausal and post-menopausal years. Continue Reading Essentials by Revivele women's supplements were developed by Dr. Kavita Desai, Pharm. D. Post this Essentials by Revivele is a comprehensive, easy-to-use supplement system tailored to help improve and support women’s overall health and longevity, especially during perimenopausal and post-menopausal years. Essentials by Revivele includes clinically proven ingredients and dosage amounts based on clinical studies linked to better long-term health outcomes and disease prevention. It is also economical and easy to use, as purchasing each ingredient as a separate supplement would require taking nearly 60 pills a day and cost more money overall. Founder Dr. Kavita Desai, Pharm. D., a Doctor of Pharmacy, brain health advocate, and published author of "Lady Parts: Putting Women's Health Back Into Women's Hands," spent over two years formulating 48 science-backed vitamins, minerals, herbs, and functional mushrooms into an efficient and thoughtfully formulated supplement system that supports women's health. Essentials by Revivele is designed to address cognitive function, longevity, hormonal balance, and common symptoms associated with perimenopause and menopause, among other preventative aspects of women's health. This strategic supplement system is also aimed at reducing the risk of chronic diseases like Alzheimer's, which affects twice as many women as men worldwide. Dr. Desai started her career as a hospital-based pharmacist, eventually opening her own integrated medical center and clinical pharmacy focused on pain management and preventative medicine. At that time in Dr. Desai's career, her mother was diagnosed with early-onset Alzheimer's. Dr. Desai learned first-hand about the many disease risks women face as they enter the perimenopausal years and how important it is for women to prioritize their own health. She pivoted her career to addressing symptom relief and disease prevention in women, with a special focus on improving brain health, and prevention of Alzheimer's and other chronic diseases. In 2021 she founded Revivele, which helps fill this gap in health care by providing tangible solutions, and is an educational resource for women. "Through running my own integrated medical center, witnessing the decline of my mother's health and hearing from thousands of women in our Revivele online community, I'm aware of the challenges women face in prioritizing themselves and their health," says Dr. Desai. "I created Essentials by Revivele to take the guesswork out of supplementation for women, help them take a proactive approach to their health, and feel their best through their perimenopausal years and beyond." The Essentials by Revivele system is comprised of six daily products carefully formulated to work in harmony and be taken throughout the day. Designed for enhanced tolerability and absorption, Essentials aims to help improve all facets of women's health, especially focusing on cognitive function, energy, sleep, mood, gut health, immunity and hormone balance. The products include: Inhale (enteric-coated tablets) – A blend of herbs, vitamins, and minerals for improved energy production, reducing inflammation, burning fat, and boosting brain function. Key ingredients: Vitamin C, B-vitamins, choline, selenium, chromium, inositol, berberine, coenzyme Q10, whole coffee fruit extract, ashwagandha, alpha lipoic acid. Flow (enteric-coated tablets) – A midday adaptogenic supplement designed for the ups and downs of a busy day. Flow helps to boost brain function, regulate energy and blood sugar, help the body cope with physical and chemical stressors, and boost immunity. Key ingredients: zinc, Ceylon cinnamon, berberine, ashwagandha, tulsi/holy basil, turmeric, piperine, rhodiola. Enhance (soft-gels) – A rich mix of high-dose Omega-3 fish oils and vital fat-soluble vitamins designed for maximum absorption. These soft gels work to strengthen heart and brain functions, as well as improve mood, skin, and bone health. Key ingredients: Vitamin D₃, vitamin E, vitamin K₂-MK7, Omega-3 fatty acids (EPA, DHA). Bloom (gummies) – An exclusive blend of seven functional mushrooms that are a tasty way to supercharge the immune system, boost energy levels, bolster daily resilience, reduce inflammation, while also improving brain and digestive functions. Naturally colored and flavored, these gummies have a delicious lemon soda taste, and are sugar-free. Key ingredients: Maitake, cordyceps, lion's mane, reishi, wild chaga, tremella, turkey tail mushrooms. Flourish (capsules) – Consists of 48 billion beneficial microbes that work to strengthen the gut's lining, improving digestion and absorption of nutrients. This proprietary probiotic blend will help improve many dimensions of overall health. Key ingredients: Proprietary blend consisting of seven unique probiotic strains. Exhale (capsules) – Fosters a relaxing and restorative sleep for body and mind alike. Encourages muscle relaxation and a reset of sleep cycles to enhance immune function and restore brain function. Key ingredients: Magnesium glycinate, L-theanine, melatonin. "I'm proud that Essentials by Revivele greatly surpasses all other products on the market today, which often contain too few key ingredients needed to make a meaningful impact on one's health," said Dr. Kavita Desai, Pharm. D., Founder and CEO, Revivele. "Because a piecemeal approach to supplementation can be confusing, expensive and ineffective, I meticulously formulated this comprehensive supplement system to be easy to follow and offer maximum absorption and efficacy to support a woman's health throughout all the decades of her adult life." At launch, a 30-day supply of Essentials by Revivele is available at Revivele.com, for $399, which equates to approximately $13 per day. For more information about Revivele and Dr. Desai, visit Revivele.com, or check out @Revivele.Inc on Instagram, Revivele.Inc on Facebook, and Revivele on LinkedIn. About Revivele Revivele is a female-focused healthcare brand dedicated to women's long-term health, perimenopausal support and overall disease prevention. Founded by accomplished pharmacist, published author, and women's health specialist, Dr. Kavita Desai, Pharm.D., the company's mission is to help fill the gap in health care and empower women to take control of their own well-being. Dr. Desai created Revivele to build a sense of community for women, provide compassionate, factual information, and actionable solutions to help improve their health outcomes and better advocate for their needs. Women face challenges that men don't – which is why Revivele provides female-led, research-focused health information and solutions to help women live their best, healthiest lives in the present and future. Alafair Hall [email protected] 415-730-9044 SOURCE Revivele

08 Sep 2023

·www.pmlive.com

Octopus clinical trial for progressive MS advances with new site in Wales

The world’s first multi-arm, multi-stage (MAMS) platform trial for progressive multiple sclerosis (MS), Octopus, has opened a new site at the University Hospital of Wales in Cardiff. The Welsh site is one of up to 30 other sites set to open around the UK. Estimated to affect over 130,000 people in the UK, including 5,600 people in Wales, MS is a disabling neurological disease that disrupts communication between the brain and body. Shelley Elgin, country director at MS Society Cymru, said: "We’re delighted to see the Octopus trial site opening in Cardiff. "There are thousands with progressive forms who have nothing to stop their MS getting worse. We won’t stop until we have treatments that transform the lives of everyone with MS." Launched in April 2023 and funded by the UK’s MS Society, the Octopus trial is led by researchers at the Queen Square MS Centre and MRC Clinical Trials Unit at University College London (UCL). Designed to allow multiple drugs to be tested at the same time using a single control group, the trial uses MRI scans to give an early indication as to whether a drug may or may not be effective before disability effects set in. Currently, the trial is testing two drugs, metformin, which is approved for diabetes in the UK, and alpha lipoic acid, which is approved for neuropathy – a type of nerve damage – in Germany. Both drugs have shown potential to help protect nerves. Octopus, which aims to enrol a minimum of 1,200 people with progressive MS across the next six years, has also recruited its first participant to the new site in Cardiff. Dr Emma Tallantyre, Octopus recruitment lead and principal investigator at the University Hospital of Wales, said: "Octopus is a landmark trial, one of the first of its kind in MS... This is such an exciting opportunity for people… who currently have no or limited treatment options to have something that could be disease modifying.” Anyone in the UK living with primary or secondary progressive MS can register their interest through the UK MS Register.

Clinical Study

100 Deals associated with Lipoic acid

External Link

KEGG	Wiki	ATC	Drug Bank
-	Lipoic acid	A10B	DB00166

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic Neuropathies	DE	-	01 Jan 1966

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus	Phase 3	CN	NovaMed Pharmaceuticals, Inc.	-
Acne Vulgaris	Phase 2	CN	Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.	11 Jul 2019
Diabetic peripheral neuropathy	Phase 1	CN	Yabao Pharmaceutical Group Co., Ltd.	08 Jul 2021
Diabetes Mellitus, Type 2	Preclinical	QA	Hamad bin Khalifa University	17 Sep 2019
Insulin Resistance	Preclinical	QA	Hamad bin Khalifa University	17 Sep 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


DDW2024	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	-	ALA-SM (LUDLEV® 300 mg/46.2 mg)	rejzyzqkip(xoiieyjfup) = reported by 8% of group A and 4% of group B, but no participants were discontinued hyfmvlabdb (cwscqvcvtv ) View more	-	19 May 2024
				Placebo
DDW2024	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	-	ALA-SM (LUDLEV® 300 mg/46.2 mg)	idwwhwcufl(rgposiqphl) = noteworthy trend towards reduction vjspzbyoay (srhtwmvarh ) View more	-	19 May 2024
				Placebo
DDW2024	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	-	ALA-SM (LUDLEV® 300 mg/46.2 mg)	cfidnpkrvu(snjhlwghnm) = reported by 8% of group A and 4% of group B, but no participants were discontinued msqanleaum (kqpjhotvkh ) View more	-	19 May 2024
				Placebo
DDW2024	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	-	ALA-SM (LUDLEV® 300 mg/46.2 mg)	tiepergxuj(xonncyqekt) = noteworthy trend towards reduction lyixnhcpwn (mjuidbhpoh ) View more	-	19 May 2024
				Placebo
IRCT20190406043177N1 (not available, Pubmed \| Int J Fertil Steril)	Phase 3	Abortion, Habitual sperm DNA damage \| oxidative stress	37	Alpha-Lipoic Acid (ALA) 600 mg/day	aktmwssgtq(ekgkpuzjop) = rbymvnxkvj ewrkxrttwz (ottfqhlrul )	Positive	01 Jan 2023
				Placebo	aktmwssgtq(ekgkpuzjop) = ijjxrlzqce ewrkxrttwz (ottfqhlrul )
ESGO2022	Not Applicable	Squamous Intraepithelial Lesions sedimentation \| high-sensitivity CRP \| fibrinogen ... View more	100	Alpha-lipoic acid (ALA) supplementation	ipedrgjskn(pcyvomrlix) = ixnaozbtjk mfqlwwgqij (orktuzxeaj )	Negative	20 Oct 2022
				Placebo	ipedrgjskn(pcyvomrlix) = orgvtbmcms mfqlwwgqij (orktuzxeaj )
NCT01054768 (CTgov)	Phase 2	Inflammation \| Anemia, Sickle Cell	37	alpha-lipoic acid+acetyl-L-carnitine (Alpha-lipoic Acid and Acetyl-L-carnitine)	ceeflngvvv(ufdzwxwisq) = qefnztmxbt dadrwezupe (bpomsxnsoj, snpossjdra - pfclwfuxnv) View more	-	03 Aug 2021
				Control (Placebo)	ceeflngvvv(ufdzwxwisq) = xhsixiyxor dadrwezupe (bpomsxnsoj, elpxkresfh - vngpvgbkbm) View more
NCT00962429 (CTgov)	Phase 2	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	7	lipoic acid (Lipoic Acid)	sfmufcrsqc(vxtvqknvnf) = jokykvjheb zfgjgbumkq (tcaaludmrm, hzmkoupygh - rtlxoraxly) View more	-	19 Aug 2020
				lipoic acid (Placebo)	sfmufcrsqc(vxtvqknvnf) = bxoxtpglwo zfgjgbumkq (tcaaludmrm, gsgnlkhivv - mgxqxmmsip) View more
NCT02613572 (ALA, CTgov)	Phase 1/2	Age Related Macular Degeneration \| Geographic Atrophy	68	Placebo	jjnsqssgix(iboclaxztq) = mrpmuddgen ikqakqaioe (tnyawcgcfq, wenvsfxjup - mrqahumzkw) View more	-	06 Aug 2020
SO044 (ERA2020)	Not Applicable	reactive oxygen species (ROS) \| miRNA-126 \| CoQ10	60	Selenium	jgnjnkvbjh(uxsskxcynx) = osvaxteafl igkmtsbhfa (sdjlabqclm )	Positive	06 Jun 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis